NORTHAMERICAN PHARMACEUTICAL SERVICES INC. WILL PUSH MAIL-ORDER
NORTHAMERICAN PHARMACEUTICAL SERVICES INC. WILL PUSH MAIL-ORDER incentives under a marketing agreement announced April 20 with an Elmsford, N.Y. mail-service firm, Employee Pharmaceutical Inc. (EPI). Northamerican Pharmaceutical Services (NPS), a Phoenix-based drug benefit firm, markets a prescription service called Managed Pharmaceutical Care. NPS was started in mid-1987 under the direction of Benjamin Ward, Sr., a former executive of McKesson's Pharmaceutical Card Service (PCS). Ward is chairman of NPS. NPS claims that its drug program "is an extraordinary contrast to other prescription drug plans." Promotion material for NPS says it "offers flexible plan design and reimbursement formula selection." The company reports that it can tailor programs to blend "coinsurance and annual maximums . . . with generic drug substitution and mail-service pharmacy incentives." Prior to the contract with EPI, NPS already had mail-order experience. One of the initial NPS clients is the Blue Cross/Blue Shield Plans of Arizona. From Jan. 1 of this year, NPS has been providing mail-service pharmacy to 33,000 enrollees in a Medicare supplement program run by the Arizona Blues. EPI is the mail-order subsidiary of EPIC Health Care Group. EPIC says that it provides mail-order services to 150 customers with over 2 mil. enrollees. Two customers account for nearly 50% of that business. In the three months ended Feb. 29, EPIC reported sales of $ 7.9 mil. The company's cost of goods was $ 6.3 mil., indicating a markup of 25%. The company showed an operating income of $ 92,000 in the quarter. NPS President Robert McLaughlin maintained that the agreement with EPI should combine with the NPS management program to "enable NPS to offer clients a 20% to 40% savings, compared to most other prescription drug programs."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth